Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Journal article (2019)

Authors

Salo Ooft Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Oncode Institute
Fleur Weeber Oncode Institute, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis
K Dijkstra Oncode Institute, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis
Chelsea M. McLean Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Oncode Institute
Sovann Kaing Oncode Institute, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis
Erik van Werkhoven Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis
Luuk Schipper Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Oncode Institute
Louisa Hoes Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Oncode Institute
L.F.A. Wessels Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, Pattern Recognition and Bioinformatics - EEMCS , Oncode Institute
More Authors... External organisation
Research Group
Pattern Recognition and Bioinformatics (EEMCS) (TU Delft)
Copyright: © 2019 Salo N. Ooft, Fleur Weeber, Krijn K. Dijkstra, Chelsea M. McLean, Sovann Kaing, Erik van Werkhoven, Luuk Schipper, Louisa Hoes, L.F.A. Wessels, More Authors
DOI: https://doi.org/10.1126/scitranslmed.aay2574
More Info
expand_more

Published Date

2019

Language

English

Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Faculty

Electrical Engineering, Mathematics and Computer Science

Department

Intelligent Systems

Research Group

Pattern Recognition and Bioinformatics

Abstract

There is a clear and unmet clinical need for biomarkers to predict responsiveness to chemotherapy for cancer. We developed an in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC). In a prospective clinical study, we show the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy. Our PDO test predicted response of the biopsied lesion in more than 80% of patients treated with irinotecan-based therapies without misclassifying patients who would have benefited from treatment. This correlation was specific to irinotecan-based chemotherapy, however, and the PDOs failed to predict outcome for treatment with 5-fluorouracil plus oxaliplatin. Our data suggest that PDOs could be used to prevent cancer patients from undergoing ineffective irinotecan-based chemotherapy.

Files

Eaay2574.full.pdf
(pdf | 0.738 Mb)
Unknown license